Scarica l'app Stockscreener
0.945
0.78%
0.0073
Dopo l'orario di chiusura:
.96
0.015
+1.59%
Precedente Chiudi:
$0.9377
Aprire:
$0.95
Volume 24 ore:
130.19K
Relative Volume:
0.59
Capitalizzazione di mercato:
$46.63M
Reddito:
$2.43M
Utile/perdita netta:
$-52.67M
Rapporto P/E:
-0.6473
EPS:
-1.46
Flusso di cassa netto:
$-33.04M
1 W Prestazione:
-4.01%
1M Prestazione:
+16.65%
6M Prestazione:
+1.65%
1 anno Prestazione:
-26.74%
Intervallo 1D:
$0.9125
$0.95
Intervallo di 1 settimana:
$0.8894
$1.05
Portata 52W:
$0.6301
$1.58
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Nome
Lucid Diagnostics Inc
Settore
Industria
Telefono
212 949 4319
Indirizzo
360 MADISON AVENUE, NEW YORK
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-12-27 | Iniziato | Ascendiant Capital Markets | Buy |
| 2021-11-08 | Iniziato | BTIG Research | Buy |
| 2021-11-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Iniziato | Needham | Buy |
Lucid Diagnostics Inc Borsa (LUCD) Ultime notizie
Lucid Diagnostics expands direct contracting for cancer testing - Investing.com
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers - PR Newswire
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024 - GuruFocus.com
PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024 - StockTitan
Lucid Diagnostics (NASDAQ:LUCD) Trading 1.5% HigherShould You Buy? - MarketBeat
Lucid Diagnostics (NASDAQ:LUCD) Trading 1.5% Higher – Here’s What Happened - Defense World
An unusual mascot and a former Cincinnati Bengal fight esophageal cancer - MM+M Online
Lucid Diagnostics to Participate in Upcoming Investor Conferences - GuruFocus.com
Lucid Diagnostics gets notice of allowance for patent underlying its esoguard esophageal DNA test - MSN
Lucid Diagnostics secures US patent for esophageal cancer test - Investing.com
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test - StreetInsider.com
Lucid Diagnostics stock maintains Buy rating from BTIG - Investing.com India
Lucid Diagnostics stock maintains Buy rating from BTIG By Investing.com - Investing.com South Africa
Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players - Aktiellt
PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care - StockTitan
October's 4 Best Penny Stocks: High-Risk, High-Reward Picks - Benzinga
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit - PR Newswire
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024 - StreetInsider.com
Contrasting enVVeno Medical (NASDAQ:NVNO) and Lucid Diagnostics (NASDAQ:LUCD) - Defense World
Lucid Diagnostics Inc. (NASDAQ:LUCD) Position Trimmed by Nantahala Capital Management LLC - Defense World
Lucid Diagnostics' SWOT analysis: esophageal cancer screening stock faces pivotal year - Investing.com
Lucid Diagnostics Announces Multiple Presentations at the Upcomi - GuruFocus.com
Lucid Diagnostics Strengthens and Expands Market Access and Dire - GuruFocus.com
LUCDLucid Diagnostics Inc. Latest Stock News & Market Updates - StockTitan
PAVMPAVmed Inc. Latest Stock News & Market Updates - StockTitan
American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test - StockTitan
American Foregut Society's 2024 Annual Meeting to Highlight Luci - GuruFocus.com
Lucid Diagnostics to be deconsolidated from PAVmed’s financial statements - Medical Buyer
Lucid Diagnostics to be deconsolidated from PAVmed's financial statements - Seeking Alpha
PAVmed moves to deconsolidate Lucid Diagnostics - Investing.com
PAVmed moves to deconsolidate Lucid Diagnostics By Investing.com - Investing.com UK
PAVmed’s Strategic Overhaul to Secure Nasdaq Compliance - TipRanks
PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements - StockTitan
Lucid Diagnostics (NASDAQ:LUCD) Given New $7.25 Price Target at Ascendiant Capital Markets - Defense World
Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress - StockTitan
Lucid Diagnostics partners with Front Line to boost cancer detection in firefighters - Investing.com
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health - Yahoo Finance
Wall Street analysts’ outlook for Lucid Diagnostics Inc (LUCD) - SETE News
Stock Market Recap: Lucid Diagnostics Inc (LUCD) Concludes at 0.84, a -2.10 Surge/Decline - The Dwinnex
Lucid Diagnostics reports high accuracy in esophageal test study - Investing.com India
Behind Lucid Diagnostics Inc’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
Analyzing LUCD’s current quarter earnings projections - US Post News
Lucid Diagnostics reports high accuracy in esophageal test study By Investing.com - Investing.com Australia
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer - Yahoo Finance
Lucid Diagnostics (NASDAQ:LUCD) Rating Reiterated by Canaccord Genuity Group - Defense World
Lucid Diagnostics Launches New Corporate Website - Longview News-Journal
PAVmed Inc (PAVM) Q2 2024 Earnings Call Transcript Highlights: R - GuruFocus.com
PAVmed’s EsoGuard revenue for Q2 2024 stands at USD 1.0M - Medical Buyer
Lucid Diagnostics (NASDAQ:LUCD) Lifted to Strong-Buy at Canaccord Genuity Group - Defense World
Cantor Fitzgerald stays bullish on Lucid Diagnostics, keeps $3 target - Investing.com
Lucid Diagnostics maintains Buy rating, $2.50 target amid growth By Investing.com - Investing.com Australia
Lucid Diagnostics Inc Azioni (LUCD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.47%
1.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):